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Summary
Background Several new genes and clinical subtypes have been identified since the
publication in 2014 of the report of the last International Consensus Meeting on
Epidermolysis Bullosa (EB).
Objectives We sought to reclassify disorders with skin fragility, with a focus on EB,
based on new clinical and molecular data.
Methods This was a consensus expert review.
Results In this latest consensus report, we introduce the concept of genetic disorders
with skin fragility, of which classical EB represents the prototype. Other disorders
with skin fragility, where blisters are a minor part of the clinical picture or are not
seen because skin cleavage is very superficial, are classified as separate categories.
These include peeling skin disorders, erosive disorders, hyperkeratotic disorders,
and connective tissue disorders with skin fragility. Because of the common manifes-
tation of skin fragility, these ‘EB-related’ disorders should be considered under the
EB umbrella in terms of medical and socioeconomic provision of care.
Conclusions The proposed classification scheme should be of value both to clini-
cians and researchers, emphasizing both clinical and genetic features of EB.
What is already known about this topic?
• Epidermolysis bullosa (EB) is a group of genetic disorders with skin blistering.
© 2020 The Authors. British Journal of Dermatology
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• The last updated recommendations on diagnosis and classification were published
in 2014.
What does this study add?
• We introduce the concept of genetic disorders with skin fragility, of which classical
EB represents the prototype.
• Clinical and genetic aspects, genotype–phenotype correlations, disease-modifying
factors and natural history of EB are reviewed.
• Other disorders with skin fragility, e.g. peeling skin disorders, erosive disorders,
hyperkeratotic disorders, and connective tissue disorders with skin fragility are clas-
sified as separate categories; these ‘EB-related’ disorders should be considered
under the EB umbrella in terms of medical and socioeconomic provision of care.
Genetic disorders with skin fragility (SF) are characterized by
structural anomalies that reduce the resilience of skin to
mechanical stress. Depending on the location of the molecular
and structural defect within the skin, clinical manifestations
may include peeling, blisters, erosions, ulceration, wounds or
scars. In April 2019, a number of leading experts met in Lon-
don, UK, to review the relevant data and to revise the system
of classification of these disorders, considering in particular
epidermolysis bullosa (EB), and focusing on the molecular
aetiology whenever possible.
EB is the prototypic group of disorders with SF defined by blis-
tering from minimal mechanical trauma with disruption at the
dermoepidermal junction (Table 1 and Figure S1; see Supporting
information).1 The four major classical EB types are – EB simplex
(EBS), junctional EB (JEB), dystrophic EB (DEB) and Kindler EB
(KEB). Other disorders with SF, where blisters are only a minor
part of the clinical picture or are not seen because skin cleavage is
very superficial, are classified as separate categories. These include
peeling skin disorders, erosive disorders, hyperkeratotic disorders,
and connective tissue disorders with SF (Table 2 and Tables S1–
S5; see Supporting information). Because of the common manifes-
tation of SF, these ‘EB-related’ disorders should be taken into
account in the differential diagnosis.
The proposed system remains largely clinically oriented,
because the classification of patients with SF begins at the bed-
side based on personal and family history, and the presence or
absence of specific clinical features. It is only later that labora-
tory diagnosis enables more accurate subclassification of these
patients based on molecular findings (Tables 3–5). The EB clas-
sification is complex because mutations in the same gene may
be inherited in an autosomal dominant or recessive manner and
may result in distinct clinical phenotypes (e.g. KRT5, KRT14,
PLEC, COL17A1 or COL7A1). On the other hand, in DEB and EBS,
similar phenotypes may be either dominant or recessive, or may
be caused by mutations in different genes (e.g. COL7A1, KRT5,
KRT14, PLEC, DST, EXPH5 or KLHL24).
If EB is suspected, immunofluorescence mapping and
molecular genetic diagnosis should be performed at an early
Table 1 Classification of classical epidermolysis bullosa (EB)
Classical types of EB
Level of skin cleavage EB type Inheritance Mutated gene(s) Targeted protein(s)
Intraepidermal EB simplex Autosomal dominant KRT5, KRT14 Keratin 5, keratin 14
PLEC Plectin
KLHL24 Kelch-like member 24
Autosomal recessive KRT5, KRT14 Keratin 5, keratin 14
DST Bullous pemphigoid antigen 230 (BP230)
(syn. BPAG1e, dystonin)
EXPH5 (syn. SLAC2B) Exophilin-5 (syn. synaptotagmin-like protein
homolog lacking C2 domains b, Slac2-b)
PLEC Plectin
CD151 (syn. TSPAN24) CD151 antigen (syn. tetraspanin 24)
Junctional Junctional EB Autosomal recessive LAMA3, LAMB3, LAMC2 Laminin 332
COL17A1 Type XVII collagen
ITGA6, ITGB4 Integrin a6b4
ITGA3 Integrin a3 subunit
Dermal Dystrophic EB Autosomal dominant COL7A1 Type VII collagen
Autosomal recessive COL7A1 Type VII collagen
Mixed Kindler EB Autosomal recessive FERMT1 (syn. KIND1) Fermitin family homolog 1 (syn. kindlin-1)
© 2020 The Authors. British Journal of Dermatology
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stage to determine the precise subtype, improve prognosti-
cation, and enable genetic counselling, prenatal diagnosis,
inclusion in clinical trials and precision medicine.2,3 Guide-
lines for laboratory diagnosis of EB have been published
recently,2 and will therefore not be discussed in this article.
Unifying clinical and molecular aspects, the previously
introduced ‘onion skin’ approach for subclassification of
EB,1 including the major EB type (based on level of skin
cleavage), the inheritance pattern and the clinical and
molecular features has proved to be useful, and is further
recommended.
The concept of syndromic SF disorders has been proposed
recently,4 and comprises those entities which are characterized
by primary manifestations of other organs or systems such as
the gastrointestinal or urogenital tract, myocardium, skeletal
muscle, etc. (Table S1; see Supporting information). In con-
trast to this, severe EB subtypes with long-lasting skin and
mucosal defects over large surface areas, in particular severe
recessive DEB (RDEB), evolve with secondary extracutaneous
complications.5,6
Classical types of epidermolysis bullosa
The main clinical and genetic features of classical types of EB
are described in Appendix S1 (see Supporting information).
Clinical aspects are illustrated in Figures 1–5 and Figures S2–
S4 (see Supporting information).
Epidermolysis bullosa simplex
EBS is defined by skin blistering due to cleavage within the
basal layer of keratinocytes. In most cases, EBS is inherited
in an autosomal dominant manner; autosomal recessive
inheritance is rare in Western countries but quite common
in some regions in the world.7,8 There is a broad spectrum
of clinical severity ranging from minor blistering on the feet,
to subtypes with extracutaneous involvement and a lethal
outcome. The genetic background is complex with mutations
in seven distinct genes. New genes, KLHL249,10 and CD151,11
have been identified since the previous classification and
extend the spectrum of EBS; still, a certain percentage of
cases remain genetically unsolved. EBS is the most common
EB type, with the majority of mild cases remaining under-
diagnosed. Figures from the USA suggested a total incidence
of 787 per million live births, and a prevalence of six per
million.12
The common EBS subtypes are caused by monoallelic muta-
tions within the genes encoding keratin 5 or 14, and com-
prise: localized (previously known as Weber–Cockayne),
intermediate (previously known as generalized intermediate or
K€obner) and severe (previously known as generalized severe
or Dowling–Meara) EBS. Rare EBS subtypes are clinically
heterogeneous and include several syndromic disorders
(Table 3). Genetically, conditions are either autosomal domi-
nant or recessive, some of them being caused by specific
Table 2 Other disorders with skin fragilitya
Level of skin
cleavage Disorder name Inheritance Mutated gene(s) Targeted protein(s)
Peeling skin disorders
Intraepidermal Peeling skin disorders Autosomal recessive TGM5 Transglutaminase 5
CSTA Cystatin A
CTSB Cathepsin B












Hyperkeratotic disorders with skin fragility
Intraepidermal Keratinopathic ichthyoses Autosomal dominant KRT1, KRT10, KRT2 Keratin 1, 10, 2
Autosomal recessive KRT10 Keratin 10
Intraepidermal Pachyonychia congenita Autosomal dominant KRT6A, KRT6B, KRT6C,
KRT16, KRT17
Keratin 6A, 6B, 6C, 16, 17
Connective tissue disorder with skin fragility
Dermal Syndromic connective tissue
disorder with skin fragility
Autosomal recessive PLOD3 Lysyl hydroxylase 3
aFor details, see Tables S1–S5 (see Supporting information); balso hyperkeratotic features.
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mutations with distinct molecular and phenotypic conse-
quences that are not fully understood. A few cases of EBS
caused by mutations in ITGB4 or COL17A1 (genes usually asso-
ciated with JEB) that disrupt the cytoplasmic domains of the
respective proteins have been reported.13,14
Junctional epidermolysis bullosa
JEB is an autosomal recessive disorder characterized by skin
blistering with a plane of cleavage through the lamina lucida
of the cutaneous basement membrane zone (BMZ). The sever-
ity varies considerably across the two major subtypes, inter-
mediate and severe, with the latter associated with early
lethality in the first 6–24 months of life. Epidemiological data
indicate that JEB is less common than simplex or dystrophic
types of EB. Figures from the USA suggested a total incidence
of just over two per million live births; however, prevalence
rates lower than this likely reflect the short life expectancy of
the severe form.12,15
The two major subtypes of JEB are severe JEB (previously
known as JEB generalized severe, Herlitz JEB) and intermediate
JEB (previously known as JEB generalized intermediate, non-
Herlitz JEB). While biallelic mutations in one of the three
genes encoding the subunit chains of laminin 332 (LAMA3,
LAMB3, LAMC2) give rise to either of these forms, biallelic
mutations of the type XVII collagen gene (COL17A1) can also
result in intermediate and rarely in severe JEB phenotypes.16
Rare JEB subtypes are clinically and genetically heterogeneous
and include several syndromic disorders (Table 4).
Dystrophic epidermolysis bullosa
DEB is characterized by a plane of skin cleavage just beneath
the lamina densa in the most superficial portion of the der-
mis. Ultrastructurally, this corresponds to the level of the
anchoring fibrils, reflecting the underlying molecular pathol-
ogy in the gene coding for the main component of these
structures, type VII collagen. DEB may be inherited as a
dominant or recessive trait; generally, RDEB is more severe
than dominant disease (DDEB); however, there is consider-
able phenotypic overlap between types. The hallmark of DEB
is that of scarring following blistering, both in the skin and
in a variety of mucosae. Milia are also a specific finding in
areas of healed blistering in DEB. Secondary extracutaneous
Table 3 Epidermolysis bullosa simplex (EBS) clinical subtypes
Most common EBS clinical
subtypes Targeted protein(s)
Autosomal dominant EBS
Localized Keratin 5, keratin 14
Intermediate Keratin 5, keratin 14
Severe Keratin 5, keratin 14
With mottled pigmentation Keratin 5a






Intermediate or severe Keratin 14, keratin 5
Intermediate Plectin











Severe with pyloric atresia Plectin
Localized with nephropathy CD151 (CD151 antigen)
(syn. tetraspanin 24)
aTypical recurrent mutation in keratin 5, but cases with other
keratin 5, keratin 14 or exophilin-5 mutations have been
reported; bold, syndromic EBS subtypes.
Table 4 Junctional epidermolysis bullosa (JEB) clinical subtypes




Intermediate Type XVII collagen
With pyloric atresia Integrin a6b4
Localized Laminin 332, type XVII collagen,
integrin a6b4, integrin a3
subunit
Inversa Laminin 332
Late onset Type XVII collagen





LOC, laryngo–onycho–cutaneous. aJEB severe is rarely caused by
pathogenic variants affecting the type XVII collagen gene; bold,
syndromic JEB subtypes.
Table 5 Dystrophic epidermolysis bullosa (DEB) clinical subtypes
DEB subtypes Targeted protein














Dominant and recessive (compound heterozygosity)
DEB, severe Type VII collagen
bold, most common subtypes.
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complications are common in the more severe forms of
RDEB. Estimates of the incidence and prevalence of DEB vary,
reflecting differences in recruitment to patient cohorts in dif-
ferent countries. The incidence of DDEB in Norway and the
USA has been reported as 14 and 25 per million live
births,17 respectively, and that of RDEB in the USA at 305
per million.15 Figures for prevalence of all types of DEB have
been estimated at approximately six per million in the USA15
and Spain,18 eight per million in Australia19 and 20 per
million in Scotland,20 the latter probably reflecting greater
capture rather than a true higher prevalence.
All subtypes of DEB, both dominant and recessive, are
caused by mutations in the gene coding collagen VII, COL7A1,
the major component of the anchoring fibrils at the cutaneous
BMZ. Major subtypes of DEB include localized DDEB (previ-
ously encompassing nails only, pretibial and acral DDEB),
intermediate DDEB (previously known as generalized DDEB),






Figure 1 Epidermolysis bullosa simplex (EBS). (a) Neonatal severe EBS with widespread skin blistering, ulceration and crusting. Nails may be
thickened. (b) Beyond the first months or year of life, arcuate or herpetiform blistering and crusting on an inflammatory base is typical of severe
EBS. (c) Tense blisters and healing erosions affecting sites of friction on the feet in localized EBS. (d) Plantar keratoderma, here in severe EBS, is
found in all three common EBS subtypes. (e) Nails may be thick and dystrophic, particularly in severe EBS. (f) Mottled hypo- and
hyperpigmentation on the lower abdomen in EBS with mottled pigmentation. (g) Superficial crusts, erosions and scarring in KLHL24 EBS.
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Figure 2 (a) Severe junctional epidermolysis bullosa (JEB). Neonatal skin blistering and crusting. Granulation tissue of the distal digits, face and
ears are typical. In intermediate JEB, blistering may be widespread in infants (b) and lead to chronic overgranulated wounds in babies and older
individuals (c). (d) Nail loss and dystrophy with skin blistering, crusting and scarring in intermediate JEB. (e) Scarring and nonscarring alopecia
with patchily sparse hair in intermediate JEB. (f) Dental enamel defects with discoloured, pitted teeth in intermediate JEB.
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intermediate, non-Hallopeau–Siemens RDEB) and severe RDEB
(previously RDEB generalized severe, Hallopeau–Siemens
RDEB). A number of rarer forms of DEB are recognized
(Table 5).
Kindler epidermolysis bullosa
KEB is a rare type of EB with about 250 affected individuals
reported worldwide since the first description in 1954.21 It is
(a)
(b) (c)
Figure 3 (a) Localized, dominant dystrophic epidermolysis bullosa (DDEB) and intermediate recessive DEB (RDEB) often display phenotypic
overlap. Skin blistering may be limited in extent and mainly acral and over bony prominences such as elbows and knees. Blisters heal with
scarring and may be associated with milia. Nail dystrophy or loss is common. Striate hyperkeratosis of the palms and fingers may cause flexion
contractures. (b) Nail dystrophy in DDEB. (c) Lichenoid, excoriated papules of the distal limbs in EB pruriginosa.
© 2020 The Authors. British Journal of Dermatology
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Figure 4 Severe recessive dystrophic epidermolysis bullosa (RDEB). (a) Widespread skin fragility and ulceration in neonates. (b) Extensive blistering
and wounds lead to scarring and joint contractures. (c) Loss of the distal digits, digital fusion and flexion contractures increase with age. (d) Squamous
cell carcinoma is common, especially on acral sites and the lower limbs. (e) Oral blistering and ulceration with a smooth, depapillated tongue.
Progressive oral mucosal scarring leads to microstomia, loss of sulci and dental overcrowding. (f) Ectropion and pannus formation.
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more common in isolated or consanguineous populations.22,23
To avoid confusion regarding the syndromic nature of this
disorder, the designation Kindler EB is proposed instead of
Kindler syndrome. The genetic basis is represented by muta-
tions in FERMT1 (syn. KIND1), encoding fermitin family
homolog 1 (kindlin-1), an intracellular protein of focal
adhesions.
Other disorders with skin fragility
Besides the classical EB subtypes, SF is a feature of other
groups of inherited diseases, including peeling skin, erosive,
hyperkeratotic and connective tissue disorders (Table 2).
These entities resemble EB with respect to the presence of skin
and/or skin barrier defects and pathogenetic mechanisms,24
and should be considered in the differential diagnosis, in par-
ticular in the newborn. Therefore, we recommend including
the corresponding genes in next-generation sequencing tar-
geted panels for EB. The main clinical and molecular charac-
teristics of the disorders included in these groups are
summarized in Tables S3–S5 (see Supporting information).
For a detailed description we refer to the original and review
articles.25–31
Several disorders with SF deserve more detailed specifica-
tion. The acral peeling skin disease has been reported to
resemble localized EBS in infants, while in adults, characteris-
tic peeling on the extremities allows clinical diagnosis.32,33
Erosive disorders with acantholysis due to desmosomal defects
may manifest with superficial blisters, but mostly with ero-
sions. Individuals with keratinopathic ichthyoses exhibit skin
blistering at birth and in infancy, but hyperkeratosis develops
soon and dominates the clinical picture.
A disorder with acantholytic blisters of the oral mucosa has
been described in a single individual so far, resulting from a
homozygous nonsense mutation in the desmoglein 3 gene.34
Although not included as ‘classical’ EB, this group of disor-
ders is notable in that skin and often mucosal fragility are key
phenotypic features, bringing with them the same clinical bur-
den and healthcare needs. As such they should be considered




The number of pathogenic variants associated with classical EB
and other disorders with SF is steadily growing, reaching sev-
eral thousands (Human Gene Mutation Database, profes-
sional). Although many individual variants and genotype–
phenotype relationships exist, some general rules apply and
(a)
(b) (c)
Figure 5 Kindler epidermolysis bullosa. (a) Skin atrophy and poikiloderma on the hands and neck. (b) Gingivitis with gingival hyperplasia. (c)
Ectropion is common and may lead to corneal erosions.
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are outlined below. Their importance relies on their medical
relevance, in the context of prognostication of disease severity
in neonates, and in prioritization of genetic testing to save
resources. It is important to remain aware of the limitations of
these correlations when counselling patients and their families
as many exceptions to these rules have been reported.
Genotype–phenotype correlations in epidermolysis
bullosa simplex with KRT5 and KRT14 mutations
For autosomal dominant EBS with KRT5 or KRT14 pathogenic
variants, the position of the affected amino acid within the
keratin polypeptide determines the severity of the phenotype
and allows prognostication. Substitutions of highly conserved
amino acids within the helix initiation or termination motifs
impair heterodimerization of keratin 5 and 14 polypeptides
and lead to severe EBS, whereas substitutions in other regions
of the gene lead to localized EBS (www.interfil.org).35
Monoallelic in-frame deletions, splice-site or premature termi-
nation codon (PTC) variants usually lead to formation of trun-
cated proteins with dominant negative effects.36,37 Some
pathogenic variants in keratin 5 or 14 have been correlated
with a very severe clinical course.38,39 Most cases with autoso-
mal recessive EBS are caused by KRT14 nonsense or frameshift
pathogenic variants. Absence of keratin 5 has been reported in
two cases, both with early lethality.40,41
Genotype–phenotype correlations in junctional
epidermolysis bullosa
Pathogenic variants leading to absence of laminin 332 or inte-
grin a6b4 are associated with early lethality,42,43 whereas
most COL17A1 pathogenic variants result in absence of colla-
gen XVII but are associated with less severe phenotypes.44
Missense or splicing mutations allowing expression of a resid-
ual protein lead to milder phenotypes. Observations in patients
with JEB clearly show that as little as 5–10% of residual pro-
tein, even if truncated and putatively partially functional, sig-
nificantly alleviates the phenotype (reviewed in Condrat et al.44
and Has et al.45). Of particular interest are a few pathogenic
variants associated with self-improving JEB with milder than
expected phenotypes. The underlying molecular mechanisms
are alternative modulation of splicing, spontaneous read-
through of PTCs or skipping of exons containing PTCs.46–48
Genotype–phenotype correlations in dystrophic
epidermolysis bullosa
DDEB is mainly due to glycine substitutions in the collagenous
domains around the hinge region of type VII collagen corre-
sponding to exon 73 of COL7A1,49 the most common being
p.G2043R. However, there is considerable clinical variability
between individuals bearing the same glycine substitution,
even within the same family.50 In addition, some glycine sub-
stitution mutations in the collagenous triple helix are associ-
ated with RDEB and others may result in either dominant or
recessive DEB.51 Monoallelic splice-site or indel mutations
leading to in-frame skipping of entire exons (e.g. exon 87),52
or even large deletions within the triple-helical domain,53 lead
to mild localized DDEB. RDEB is caused by a broad spectrum
of pathogenic variants resulting in absence of type VII colla-
gen. Compound heterozygosity for dominant and recessive
COL7A1 mutations has been repeatedly reported to be associ-
ated with severe DEB.54 Self-improving DEB was associated
with in-frame skipping of exons (e.g. exon 36)55 or with
specific glycine substitutions.56,57 Specific glycine and arginine
substitution mutations in COL7A1 have been implicated in
RDEB inversa, with the suggestion that they may affect the
thermostability of type VII collagen.58
Disease-modifying factors
In some cases, deviations from expected genotype–phenotype
correlations can be explained by involvement of modifying
factors, either genetic or epigenetic.
One type of genetic modifier is represented by variants in cis
that may change the expression of the corresponding allele,
resulting, for example, in in-frame skipping of the exon con-
taining the disease-causing variant.59 Such an event can allevi-
ate the disease severity because truncated molecules often
retain partial function. A second type of genetic modifier is
mosaicism, either as postzygotic mosaicism for a disease-caus-
ing variant (described for COL7A1 and PKP1)60–62 or as rever-
tant mosaicism (described for KRT14,63,64 COL17A1,65–67
LAMB3,68 COL7A169–71 and FERMT172,73). Postzygotic mosai-
cism for dominant mutations may explain an apparently mild
phenotype in a parent and more severe disease in the off-
spring, while Blaschko linear areas of affected skin may result
from mosaicism for a second recessive mutation. Revertant
mosaicism has been reported in all types of EB and accounts
for skin areas with improved mechanical stability due to spon-
taneous repair of the disease-causing variant.74 Thirdly,
digenic mutations in two EB-associated genes, e.g. both KRT5
and KRT14,75 EXPH5 and COL17A176 or PLEC1 and ITGB477 vari-
ants have been reported to lead to unexpected phenotypes. A
fourth type of genetic modifier mechanism is represented by
variants in genes that are not directly associated with EB, but
their products may modulate or influence EB-associated pro-
teins. Such an example is MMP1, encoding matrix metallopro-
teinase 1, an enzyme that degrades type VII collagen. A
frequent functional genetic variant in the MMP1 promoter was
reported to be associated with higher disease severity in RDEB
due to an imbalance between type VII collagen synthesis and
degradation.78 Finally, on a consanguineous background, co-
occurrence of EB and other genetic disorders leads to com-
plex, apparently ‘new’ phenotypes.79
Epigenetic factors modulating gene expression include hete-
rochromatin components, polycomb proteins, noncoding RNA
and DNA methylation;80 such mechanisms remain to be
demonstrated in EB. Changes in gene expression of decorin
and transforming growth factor-b have been reported in
RDEB.81,82 They are either secondary effects that arise in the
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context of chronic wound healing processes and further dete-
riorate the local cutaneous environment, or are caused by dis-
crete genetic variants. Nevertheless, they represent potential
targets for therapy. Other epigenetic yet unknown factors
remain to be identified.
Finally, individual (e.g. personality, family context), socioe-
conomic (e.g. access to medical care and hygienic conditions)
and environmental factors (e.g. climate) have a significant
modulating influence on the course of EB. Taken together,
genetic, epigenetic and nongenetic modifying factors appear
to have a strong influence on EB phenotype; this variability
means that phenotypes often reflect a continuum and, as such,
strict categorization into subtypes is not always straightfor-
ward.
Natural history
The clinical features and complications of different forms of
EB often change and evolve over time and an understanding
of this is imperative to recognize different subtypes and antici-
pate the clinical course and related problems. While this natu-
ral history partly reflects changes related to different
developmental stages throughout life, certain subtypes of EB
have a natural evolution with variation in severity, either
worsening or ameliorating, or the development or loss of
specific features over time.
Distinguishing the major types of EB in the neonatal period
on the basis of clinical features is extremely unreliable and
highlights the need for rapid and accurate laboratory diagno-
sis.2 Blistering in babies often has a predilection for the
extremities and around the diaper area, but as the child devel-
ops, the pattern of blistering will usually become more char-
acteristic of its subtype. For example, in EBS localized, blisters
will form predominantly on the feet, whereas in intermediate
or severe DEB subtypes, fragility will become more marked
over bony prominences such as the knees and elbows. While
babies with severe JEB may have relatively little skin blistering
at birth, over the first few months the characteristic granula-
tion tissue affecting the face, ears and distal digits becomes
more prominent and distinctive. In KEB, early childhood blis-
tering resolves as photosensitivity and progressive poikilo-
derma become more evident. Some sequelae of EB are
irreversible and progressive, for example skin and oral muco-
sal scarring or nail loss in DEB; therefore, they tend to become
more marked with age.
In severe EBS, infants have very severe and extensive skin
blistering and this subtype can have a lethal course. However,
the natural history is one of progressive improvement over
time, such that adults may have very limited blistering con-
fined largely to acral sites. The clinical features of EBS with
mottled pigmentation also vary with time, often with blister-
ing improving throughout childhood, paralleled by the devel-
opment of the characteristic pigmentary changes unrelated to
previous sites of blistering and punctate palmoplantar ker-
atoses. Intermediate EBS with KLHL24 mutations is notable for
its severe skin loss at birth which ameliorates with age, and
also by the development of cardiomyopathy in early adult-
hood. Similarly, in EBS with PLEC mutations, SF is accompa-
nied by the onset of progressive muscular dystrophy at any
point between infancy and adulthood, and has also been asso-
ciated with cardiomyopathy.
The extent and pattern of blistering may vary in distinct
forms of EB. For example, RDEB inversa usually comprises
intermediate severity of generalized blistering early in life, but
later in childhood to adulthood, the sites of predilection
become markedly flexural. Pruriginosa DEB also evolves over
time, with the development of prurigo-like nodules and linear
lesions on the lower legs initially, spreading generally more
proximally and also onto the arms with time. The onset of
specific pruriginosa features may be extremely delayed, with
onset in late adulthood.83 Similarly, the distribution of local-
ized pretibial DEB evolves with age. In late-onset JEB, SF tends
to start in mid-childhood with progressive scleroderma-like
atrophy and nail changes developing subsequently. A number
of cases of severe JEB in infancy have been associated with
spontaneous amelioration and longer-term survival; in such
cases, LAMB3 mutations resulting in a truncated but partially
functional b3 laminin chain have been postulated to result in
an intermediate clinical picture.47,84,85 The mechanisms
behind the distinct patterns of distribution and their fluctua-
tion over time in different subtypes of EB are not fully under-
stood, but likely reflect specific genetic consequences at a
protein level. Further elucidation of genotype–phenotype cor-
relation in EB-causing genes as well as other genetic modifiers,
may provide some clarification in time.
In addition to disease-specific natural history, EB may be
accompanied by many secondary complications that develop
over time and often depend on the general severity of the EB
type, as well as environmental and confounding factors such
as bacterial colonization. For example, anaemia, reduced bone
mineral density, renal impairment, progressive skin contrac-
tures and the development of squamous cell carcinoma are all
potential complications of severe RDEB but there is inter-indi-
vidual variability around whether or when they may occur.86
Relevance and perspectives
Revisions of the EB classification go along with developments
in diagnostics and research, and should be a useful tool for
clinicians dealing with people with EB (for counselling, prog-
nostication, follow-up and screening for complications) and
for researchers. Emerging therapeutic options and clinical trials
open new perspectives and underscore the importance of
molecular genetics and genotype–phenotype correlations to
predict therapeutic options for precision medicine. EB-asso-
ciated proteins have distinct roles in assuring the mechanical
stability of the cells and adhesion, as well as structural and
functional particularities (e.g. laminin 332, integrin a6b487 or
collagen XVII88 in controlling keratinocyte stemness). Yet,
there are common pathogenetic mechanisms, such as chronic
tissue damage and inflammation that apply to all/several types
of EB.89 Some therapeutic principles, like induction of read-
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through of PTC mutations,90–92 RNA-based therapies (e.g.
antisense oligonucleotides for exon skipping93) or modulation
of protein misfolding,94 may be applied for different genes/
proteins, under the premise of knowledge of individual muta-
tions and their consequences. Therefore, subclassification of
EB and SF disorders on the basis of the molecular defect, and
stratification of mutations for precision medicine44 is a tempt-
ing challenge for the future.
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